BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Key Takeaways

• Tacabrutideg achieved 85% ORR in heavily pretreated R/R CLL/SLL.
• BTK degrader showed 86% ORR in BTK‑inhibitor‑naïve patients.
• ZS combo delivered 100% ORR and 98.8% uMRD4 in treatment‑naïve CLL.
• 36‑month PFS reached 95.5% for R/R CLL with ZS regimen.
• FDA granted Fast Track for tacabrutideg; EMA granted PRIME for WM.

Pulse Analysis

The emergence of BTK degraders marks a pivotal evolution beyond traditional inhibition. Tacabrutideg’s ability to eliminate both wild‑type and mutant BTK addresses a key resistance mechanism that has limited the durability of existing BTK inhibitors. By delivering an 85% response rate in heavily pretreated chronic lymphocytic leukemia and a comparable 86% rate in patients who have never received a BTK inhibitor, the agent demonstrates potential to move earlier in treatment algorithms, offering a therapeutic option for patients with high‑risk cytogenetics such as del(17p) or TP53 mutations.

Equally compelling is the all‑oral BRUKINSA + sonrotoclax (ZS) regimen, which combines a next‑generation BTK inhibitor with a short‑half‑life BCL2 antagonist. The combination achieved a 100% overall response rate and near‑complete minimal residual disease eradication in treatment‑naïve CLL, while maintaining a 95.5% progression‑free survival at three years for relapsed disease. These outcomes support a shift toward fixed‑duration, time‑limited therapy, reducing the chronic toxicity and financial burden associated with indefinite treatment courses. The deep, durable responses across diverse B‑cell malignancies suggest ZS could become a new standard for both frontline and relapsed settings.

Regulatory momentum underscores the commercial relevance of these advances. The U.S. FDA’s Fast Track designation for tacabrutideg in R/R CLL/SLL and the EMA’s PRIME status for Waldenström macroglobulinemia signal strong confidence in the drug’s clinical promise. Coupled with extensive global trial enrollment—over 1,200 patients for tacabrutideg and 2,500 for sonrotoclax—BeOne Medicines is positioned to capture a sizable share of the growing B‑cell cancer market, challenging incumbents and potentially reshaping therapeutic pathways for millions of patients worldwide.